Preventing autoimmunity protects against the development of hypertension and renal injury

Hypertension

Volumn 64, Issue 4, 2014, Pages 792-800

  Mathis, Keisa W ^a   Wallace, Kedra ^a   Flynn, Elizabeth R ^a   Maric Bilkan, Christine ^a   LaMarca, Babbette ^b   Ryan, Michael J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Autoantibodies; B lymphocytes; Pressure; T lymphocytes

Indexed keywords

ANTIBODY; CATALASE; CD20 ANTIGEN; CD45 ANTIGEN; IMMUNOGLOBULIN G; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERTENSION; IMMUNOLOGY; INBRED MOUSE STRAIN; KIDNEY; LYMPHOCYTE DEPLETION; METABOLISM; MOUSE; NEW ZEALAND BLACK MOUSE; PATHOPHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; ANTIGENS, CD20; ANTIGENS, CD45; AUTOIMMUNITY; B-LYMPHOCYTES; BLOOD PRESSURE; CATALASE; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED NZB; MICE, INBRED STRAINS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84914664859     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04006     Document Type: Article

References (45)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365: 2110-2121.
2. Kristensen BO, Andersen PL, Wiik A. Autoantibodies and vascular events in essential hypertension: A five-year longitudinal study. J Hypertens. 1984;2: 19-24.
3. Gudbrandsson T, Hansson L, Herlitz H, Lindholm L, Nilsson LA. Immunological changes in patients with previous malignant essential hypertension. Lancet. 1981;1: 406-408.
4. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103: 945-952.
5. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjögren KG, Hjalmarson A, Müller-Esterl W, Hoebeke J. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. 2000;18: 945-953.
6. Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension. 1997;29: 678-682.
7. Sabio JM, Vargas-Hitos JA, Navarrete-Navarrete N, Mediavilla JD, Jiménez-Jáimez J, Díaz-Chamorro A, Jiménez-Alonso J; Grupo Lupus Virgen de las Nieves. Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol. 2011;38: 1026-1032.
8. Ryan MJ, McLemore GR Jr, Hendrix ST. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension. 2006;48: 988-993.
9. Mathis KW, Venegas-Pont M, Masterson CW, Wasson KL, Ryan MJ. Blood pressure in a hypertensive mouse model of SLE is not salt-sensitive. Am J Physiol Regul Integr Comp Physiol. 2011;301: R1281-R1285.
10. Venegas-Pont M, Mathis KW, Iliescu R, Ray WH, Glover PH, Ryan MJ. Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2011;301: R1286-R1292.
11. Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, Glover PH, Jones AV, Drummond HA, Ryan MJ. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2010;56: 643-649.
12. Mathis KW, Venegas-Pont M, Masterson CW, Stewart NJ, Wasson KL, Ryan MJ. Oxidative stress promotes hypertension and albuminuria during the autoimmune disease systemic lupus erythematosus. Hypertension. 2012;59: 673-679.
13. LaMarca B, Wallace K, Herse F, Wallukat G, Martin JN Jr, Weimer A, Dechend R. Hypertension in response to placental ischemia during pregnancy: Role of B lymphocytes. Hypertension. 2011;57: 865-871.
14. Mathis KW, Venegas-Pont M, Flynn ER, Williams JM, Maric-Bilkan C, Dwyer TM, Ryan MJ. Hypertension in an experimental model of systemic lupus erythematosus occurs independently of the renal nerves. Am J Physiol Regul Integr Comp Physiol. 2013;305: R711-R719.
15. Ryan MJ, McLemore GR Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2007;292: R736-R742.
16. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. Angiotensin II-induced vascular dysfunction is mediated by the AT1A receptor in mice. Hypertension. 2004;43: 1074-1079.
17. Venegas-Pont M, Sartori-Valinotti JC, Maric C, Racusen LC, Glover PH, McLemore GR Jr, Jones AV, Reckelhoff JF, Ryan MJ. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2009;296: R1282-R1289.
18. White F, Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron. 1964;1: 93-102.
19. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, Guzik TJ. Inhibition and genetic ablation of the B7/ CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122: 2529-2537.
20. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension. 2011;57: 132-140.
21. Parra G, Quiroz Y, Salazar J, Bravo Y, Pons H, Chavez M, Johnson R, Rodriguez-Iturbe B. Experimental induction of salt-sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int Suppl. 2008;S55-S59.
22. Pons H, Ferrebuz A, Quiroz Y, Romero-Vasquez F, Parra G, Johnson RJ, Rodriguez-Iturbe B. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am J Physiol Renal Physiol. 2013;304: F289-F299.
23. Rodríguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ. Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2012;39: 96-103.
24. Kristensen BO, Andersen PL. Autoantibodies in untreated and treated essential hypertension. I. Acta Med Scand. 1978;203: 55-59.
25. Rollino C, Boero R, Elia F, Montaruli B, Massara C, Beltrame G, Ferro M, Quattrocchio G, Quarello F. Antiphospholipid antibodies and hypertension. Lupus. 2004;13: 769-772.
26. Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002;25: 641-646.
27. Wenzel K, Haase H, Wallukat G, et al. Potential relevance of alpha(1)- Adrenergic receptor autoantibodies in refractory hypertension. PLoS One. 2008;3: E3742.
28. Dar O, Salaman MR, Seifert MH, Isenberg DA. B lymphocyte activation in systemic lupus erythematosus: Spontaneous production of IgG antibodies to DNA and environmental antigens in cultures of blood mononuclear cells. Clin Exp Immunol. 1988;73: 430-435.
29. Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: An updated systematic review and meta-analysis. Lupus. 2013;22: 1489-1503.
30. Terrier B, Amoura Z, Ravaud P, et al; Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62: 2458-2466.
31. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6: 326-337.
32. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62: 222-233.
33. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez- Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64: 1215-1226.
34. Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, Kehry M, Anolik JH. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62: 2443-2457.
35. Gilbert EL, Mathis KW, Ryan MJ. 17ß-Estradiol protects against the progression of hypertension during adulthood in a mouse model of systemic lupus erythematosus. Hypertension. 2014;63: 616-623.
36. Shahid M, Francis J, Majid DS. Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol. 2008;295: F1836-F1844.
37. Battula S, Hao S, Pedraza PL, Stier CT, Ferreri NR. Tumor necrosis factor-alpha is an endogenous inhibitor of Na+-K+-2Cl- cotransporter (NKCC2) isoform A in the thick ascending limb. Am J Physiol Renal Physiol. 2011;301: F94-100.
38. De Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2010;298: R1136-R1142.
39. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204: 2449-2460.
40. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2010;298: R1089-R1097.
41. Rodríguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chávez M, Herrera- Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol. 2002;282: F191-F201.
42. Rodríguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gómez-Garre D, Largo R, Egido J, Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int. 2001;59: 2222-2232.
43. Saville MW, Benyunes MC, Multani PS. No clinical evidence for CD4+ cell depletion caused by rituximab. Blood. 2003;102: 408: Author reply 408-408, author reply 409.
44. Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stüve O, Shlomchik M, Eagar TN. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One. 2011;6: E17103.
45. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17(12 suppl 3): S218-S225.